Dimension Capital filed SEC Form D on June 4, 2026 seeking up to $750 million for Fund III — the firm’s third vehicle at the intersection of machine learning and life sciences.

Key facts

• Firm: Dimension Capital
• Date filed: June 4, 2026
• Target raise: Up to $750 million
• Status: Fundraising (no capital reported sold at filing)
• Focus: ML × life sciences — computation and science frontiers
• Offices: 632 Broadway, New York + San Francisco
• Prior funds: $350M Fund I (Jan 2023), $500M Fund II (Dec 2024)

Portfolio highlights

Chai Discovery, NewLimit, Earendil Labs, Odyssey Therapeutics, Aspect Biosystems, Enveda, Congruence Therapeutics, Monte Rosa Therapeutics (Nasdaq-listed).

Why this matters

Dimension has quickly become one of the leading next-generation life sciences VC firms, and a $750M Fund III would cement NYC as a major hub for computational biology capital deployment. The firm is among the top capital-deployers at the science-compute intersection globally.

Sources

1. Endpoints News: https://endpoints.news/dimension-seeks-up-to-750m-for-third-life-sciences-fund-after-string-of-success/
2. VCWire (June 8, 2026): https://vcwire.tech/2026/06/08/dimension-capital-raises-up-to-750m-for-third-fund/
3. SEC Form D filing: https://www.sec.gov/Archives/edgar/data/2134488/000101297526000522/0001012975-26-000522-index.htm